Avalo Therapeutics Inc expected to post a loss of $1.18 a share - Earnings Preview

Avalo Therapeutics

30/04/2024 13:08

* Avalo Therapeutics Inc  AVTX.OQ   AVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 2
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Avalo Therapeutics Inc
is for
a loss of $1.18 per share. 
    * The one available analyst rating on the shares is
"hold".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $35.00​, above​ its last closing price
of $16.88. ​​​

This summary was machine generated April 30 at 12:08 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)